US5641764A - Halogenated DNA ligand radiosensitizers for cancer therapy - Google Patents
Halogenated DNA ligand radiosensitizers for cancer therapy Download PDFInfo
- Publication number
- US5641764A US5641764A US08/441,116 US44111695A US5641764A US 5641764 A US5641764 A US 5641764A US 44111695 A US44111695 A US 44111695A US 5641764 A US5641764 A US 5641764A
- Authority
- US
- United States
- Prior art keywords
- dna
- halogen
- halogenated
- alkoxy
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
Definitions
- This invention relates to the use in cancer therapy of halogenated DNA ligands which induce radiation damage in DNA in response to ionising or ultraviolet radiation. More particularly, the invention is concerned with the use of such ligands as radiosensitisers.
- Radiosensitisers are substances which when present during irradiation, enhance the cytotoxic effects of radiation.
- the hypoxic radiosensitiser Misonidazole enhances the cytotoxic effect of X- and ⁇ -radiation.
- the interaction between radiation and radiosensitiser is complex and difficult to predict.
- both the radiosensitiser and the radiation are cytotoxic per se, their use in therapy is limited.
- Photosensitisers are substances which when present, enhance the cytotoxic effects of ultraviolet or visible radiation.
- photosensitisers are included in the term radiosensitisers.
- ionising radiation is used herein to include photons having enough energy to ionise a bond, such as, ⁇ , ⁇ , ⁇ rays from radioactive nuclei and x-rays.
- Incorporation of a bromine or iodine atom into DNA using BUdR or IUdR is known to sensitise DNA to breakage by ionising or ultraviolet radiation.
- the sensitisation is mediated by the uracilyl free radical formed by dissociation of the carbon-halogen bond in the BUdR or IUdR by UV and the same free radical is formed by a reaction of hydrated electrons produced by ionising radiation. It has been proposed that the uracilyl free radical initiates strand cleavage by abstraction of the hydrogen atom from the 2'-deoxyribose carbon on the adjacent nucleotide.
- the iodinated DNA ligand is a potent sensitiser of cell-kill by near UV.
- irradiation with ionising or ultraviolet radiation generates free radicals very close to, but not actually on, the DNA.
- DNA breaks are produced following abstraction of hydrogen atoms from DNA near the binding sites of the halogenated ligand.
- halogenated DNA ligands may also act as sensitisers of ionising radiation.
- Ultraviolet radiation is more effective at producing free radicals than ionising radiation.
- ultraviolet radiation has a low tissue penetration and could only be used in the treatment of superficial tumours or in the specific killing of isolated tumour cells for example, in samples of bone marrow prior to bone marrow transplantation.
- a radiosensitiser for use in cancer therapy which comprises a halogenated DNA ligand.
- a method for enhancing the susceptibility of DNA to radiation damage which comprises causing or allowing a halogenated DNA ligand to bind to the DNA before subjecting the DNA or the locus thereof to ionising or ultraviolet radiation.
- a method for inducing radiation damage in DNA which comprises causing or allowing a halogenated DNA ligand to bind to DNA and irradiating the DNA and said bound ligand or the locus thereof with ionising or ultraviolet radiation.
- the DNA ligand may be of any suitable known type e.g. an intercalating ligand such as an aminoacridine or a minor groove binding ligand such as bis-benzimidazole and those described in Baguley, V. C., (1982) J. Mol. Cell. Biochem. 43: 167-181, for example, compounds having the following structural formulae: ##STR1## wherein X is halogen.
- an intercalating ligand such as an aminoacridine or a minor groove binding ligand such as bis-benzimidazole and those described in Baguley, V. C., (1982) J. Mol. Cell. Biochem. 43: 167-181, for example, compounds having the following structural formulae: ##STR1## wherein X is halogen.
- the ligand (with its attached halogen atom) is of a type which allows enhanced uptake, by endocytosis or other means, of the radiosensitiser into cells.
- the minor groove binding ligand is a halogenated bis-benzimidazole of the general formula: ##STR2## wherein R 1 , R 2 , R 3 , R 4 and R 5 , which may be the see or different, are selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, nitro or any other suitable non-deleterious substituent; and
- R 6 is alkyl; phenyl; phenyl optionally substituted with halogen, hydroxy, alkoxy, nitro or any other suitable non-deleterious substituent; or phenylalkyl optionally substituted with halogen, hydroxy, alkoxy, nitro or any other suitable non-deleterious substituent.
- R 1 , R 2 , R 3 , R 4 and R 5 which are either the same or different, are selected from hydrogen, hydroxy, alkoxy, iodo and bromo;
- R 6 is methyl, phenyl or phenylalkyl.
- the halogenated ligand is preferably selected so as to bind at a location near the sugar chain of DNA so that the halogen free radical is sufficiently close to the potential target area in the sugar chain.
- FIG. 1 shows the 1.7% agarose gel of UV-B irradiated mixtures of plasmid DNA and iodoHoechst 33528;
- FIG. 2 shows the DNA-sequencing gels of fractionated 5'- 32 P-end-labelled restriction fragment cleavage products (SEQ ID NO. 2);
- FIG. 3 shows the pBR322 restriction fragment used in the experiments involving higher resolution (16% acrylamide) sequencing gels (SEQ ID NO. 1);
- FIG. 4 shows the relationship between UV-A dose and cell survival when iodoHoescht is added to the cell medium to a concentration of 4 ⁇ M
- FIG. 5 shows the analysis of a large number of binding sites of DNA substrates derived from M13 clones of human alpha-DNA (SEQ ID NOS. 3 and 4).
- UV-A 320-400 nm was used in preference to UV-B which closely coincides with the absorption of the halogenated nucleotides.
- iodoHoeshst 33258 photolysis involves a similar cleavage mechanism, initiated by photolysis of the carbon-iodine bond and formation of a carbon-centred free radical on the DNA ligand, which subsequently abstracts a hydrogen atom from the 5'-carbon.
- iodoHoechst is also a potent sensitiser in situ.
- irradiation resulted in 3-4-log cell kill at a UV-A dose that only marginally reduces cell survival in the absence of a sensitiser (FIG. 4). It is believed that the cell kill is mediated by DNA strand breakage.
- a further control was irradiated but did not contain iodoHoechst (lane 2).
- the final iodoHoechst concentrations in the samples were 1 ⁇ M (lane 4), 5 ⁇ M (lanes 3 and 5) and 20M (lane 6).
- EcoR1-cut pBR322 DNA was 5'- 32 P-end labelled, cut with BamH1 and the 375 bp labelled fragment isolated by preparative polyacrylamide gel electrophoresis. Samples of the labelled fragment were mixed with carrier DNA and iodoHoechst 33258 and photolysed as described in Example 1. The final concentrations of iodoHoechst were 1 ⁇ M (lane 1), 2.5 ⁇ M (lane 4), and 5 ⁇ M (lanes 2 & 5), 10 ⁇ M (lane 6), 20 ⁇ M (lane 7), and 40 ⁇ M (lane 8). The samples with matched amounts of 32 P were then analysed on a 16% polyacrylamide sequencing gel. Samples for lanes 1 and 2 were unirradiated controls and lane 8 was a Maxam-Gilbert G+A track.
- FIG. 3 (FIG. 3)
- End-labelled restriction fragments were derived from pBR322.
- the 375 bp fragments were prepared by 3'- or 5'- 32 P end labelling at the EcoR1 site, followed by subsequent cleavage with BamH1 and then isolation by preparative polyacrylamide gel electrophoresis.
- the 100bp fragments were obtained by end-labelling at the Hind IV site and subsequent cleavage with DdeI and preparative electrophoresis.
- Samples of each of the four labelled fragments were mixed with carrier DNA and subjected to UV-A photolysis with 5 ⁇ M iodoHoechst 33258 as described in Example 1. The samples were then analysed on 16% sequencing gels together with Maxam-Gilbert sequencing samples as in Example 1.
- the photolysed samples were subjected to treatment with 1M piperidine at 90° C. for 30 minutes prior to sequencing gel analysis.
- the arrows indicate the sites of photolysis cleavage relative to Maxam-Gilbert references bands. The intensity of the bands vary considerably. The asterisked arrows denote particularly weak sites.
- the bp number in the pBR322 nucleotide sequence is shown and the sequence is aligned with the zero in each number.
- FIG. 4 (FIG. 4)
- the flasks were covered with black adhesive vinyl, washed twice with ice cold PBS/EDTA and suspended with 2 ml, 0.01% Pronase. A portion of the cell suspension was washed twice with BSS, samples counted in a Coulter Counter, and various aliquots plated-out in 50 nun plastic petri dishes. The colonies were fixed and stained after 7 days and the colonies of >50 cells scored. The control cloning efficiency (>60%) was used to calculate the relative cloning efficiency of treated cells. The data shown are derived from four separate experiments, indicated by different symbols. Open symbols depict controls without iodoHoechst 33258.
- FIG. 5 (FIG. 5)
- Clone alpha 32 which contains a 340 bp insert of human alpha RI-DNA in M13 mp9, was effectively 5'-end labelled as described below and UV irradiated in the presence of iodoHoechst 33258 as described in Example 1.
- Autoradiographs of DNA sequencing gels were analysed by laser densitometry and damage sites were quantified as very strong (VS), strong (S) or medium (M).
- DNA sequences are presented 5' to 3' left to right In FIG. 5, the cleavage site is underlined and its position is given to the left of the DNA sequence.
- the iodoHoechst 33258 binding site is in capital letters.
- the procedure for effectively 5'-end labelling M13 clone alpha 32 briefly involves pulse labelling the DNA immediately after the 17 bp sequencing primer with [ 32 P]dATP, dGTP and dCTP (which effectively labels the synthesised strand at the 5'-end). This is followed by a chase with cold dATP and dTTP, which results in extensive synthesis of DNA--greater than 3000 bp.
Abstract
Description
__________________________________________________________________________ SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 4 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 55 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GAGGCCCTTTCGTCTTCAAGAATTCTCATGTTTGACAGCTTATCATCGATAAGCT55 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: TTCGAATAGCTACTATTCGACAGTTTGTA29 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: TGTAATTTGC10 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GCATATTATGC11 __________________________________________________________________________
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/441,116 US5641764A (en) | 1989-03-31 | 1995-05-15 | Halogenated DNA ligand radiosensitizers for cancer therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPJ346889 | 1989-03-31 | ||
AUPJ3468 | 1989-03-31 | ||
US76858891A | 1991-11-04 | 1991-11-04 | |
US08/441,116 US5641764A (en) | 1989-03-31 | 1995-05-15 | Halogenated DNA ligand radiosensitizers for cancer therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US76858891A Continuation | 1989-03-31 | 1991-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
US5641764A true US5641764A (en) | 1997-06-24 |
Family
ID=25643654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/441,116 Expired - Lifetime US5641764A (en) | 1989-03-31 | 1995-05-15 | Halogenated DNA ligand radiosensitizers for cancer therapy |
Country Status (1)
Country | Link |
---|---|
US (1) | US5641764A (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6194414B1 (en) * | 1995-07-28 | 2001-02-27 | The Inner And Eastern Health Care Network | Radioprotectors |
US6331286B1 (en) | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
US20020001567A1 (en) * | 1998-12-21 | 2002-01-03 | Photogen, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
WO2003011219A2 (en) * | 2001-07-27 | 2003-02-13 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6547812B1 (en) * | 2000-12-29 | 2003-04-15 | Advanced Cardiovascular Systems, Inc. | Radiation therapy using a radioactive implantable device and a radiosensitizer agent |
US20040047804A1 (en) * | 1998-10-29 | 2004-03-11 | The General Hospital Corporation, A Massachusetts Corporation | Enhanced radiation therapy |
US20040191843A1 (en) * | 2003-02-03 | 2004-09-30 | Palo Alto Institute Of Molecular Medicine | Cell-killing molecules and methods of use thereof |
US20050080019A1 (en) * | 2002-09-05 | 2005-04-14 | Nanodynamics Inc. | Radiotherapy method using x-rays |
US20070208076A1 (en) * | 1998-12-21 | 2007-09-06 | Dees H C | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US20080118567A1 (en) * | 1998-08-06 | 2008-05-22 | Provectus Pharmatech. Inc, | Medicaments for Chemotherapeutic Treatment of Disease |
US20080118578A1 (en) * | 1997-12-11 | 2008-05-22 | Dees H Craig | Topical Medicaments and Methods for Photodynamic Treatment of Disease |
US7384623B1 (en) | 1998-12-21 | 2008-06-10 | Provectus Pharmatech, Inc. | High energy phototherapeutic agents |
US20090117199A1 (en) * | 1998-08-06 | 2009-05-07 | Scott Timothy C | Method of treatment of cancer |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US7981928B2 (en) | 2002-09-05 | 2011-07-19 | Nanodynamics, Inc. | Chemotherapy method using x-rays |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415588A (en) * | 1981-07-09 | 1983-11-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Therapeutical method of treating patients with impaired immune system |
US4415589A (en) * | 1981-11-06 | 1983-11-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of carnitine and of lower acyl-carnitines in the therapeutic treatment of the pathology of the veins |
US4464393A (en) * | 1982-12-09 | 1984-08-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of alkanoyl L-carnitines in the therapeutical treatment of myopathies and muscular dystrophies |
US4663352A (en) * | 1985-06-11 | 1987-05-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of some alkanoyl L-carnitines for the therapeutical treatment of idiopathic and induced Parkinsonism |
US4751242A (en) * | 1986-08-04 | 1988-06-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of acetyl L-carnitine in the therapeutical treatment of peripheral neuropathies |
US5096694A (en) * | 1987-04-17 | 1992-03-17 | Ire-Celltarg S.A. | Compounds which are useful, in particular, for radiotherapy or imaging of cancer |
-
1995
- 1995-05-15 US US08/441,116 patent/US5641764A/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415588A (en) * | 1981-07-09 | 1983-11-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Therapeutical method of treating patients with impaired immune system |
US4415589A (en) * | 1981-11-06 | 1983-11-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of carnitine and of lower acyl-carnitines in the therapeutic treatment of the pathology of the veins |
US4464393A (en) * | 1982-12-09 | 1984-08-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of alkanoyl L-carnitines in the therapeutical treatment of myopathies and muscular dystrophies |
US4663352A (en) * | 1985-06-11 | 1987-05-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of some alkanoyl L-carnitines for the therapeutical treatment of idiopathic and induced Parkinsonism |
US4751242A (en) * | 1986-08-04 | 1988-06-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of acetyl L-carnitine in the therapeutical treatment of peripheral neuropathies |
US5096694A (en) * | 1987-04-17 | 1992-03-17 | Ire-Celltarg S.A. | Compounds which are useful, in particular, for radiotherapy or imaging of cancer |
Non-Patent Citations (52)
Title |
---|
Adams et al, Structure Activity Relationships in the Development of Hypoxic Cell Radiosensitizers, Int. J. Radiat. Biol ., 35(2):133 150 (1979). * |
Adams et al, Structure-Activity Relationships in the Development of Hypoxic Cell Radiosensitizers, Int. J. Radiat. Biol., 35(2):133-150 (1979). |
Brown, Clinical Trails of Radiosensitizers: What Should We Expect , Int. Radiat. Oncol. Biol. Phys ., 10:425 429 (1984). * |
Brown, Clinical Trails of Radiosensitizers: What Should We Expect?, Int. Radiat. Oncol. Biol. Phys., 10:425-429 (1984). |
Loewe et al, Basic Substituted 2,6 Bisbenzimidazole Derivatives, a Novel Series of Substances with Chemotherapeutic Activity, J. Arzneim. Forsch. ( Drug Res. ), 24:1927 1933 (1974) (with transl.). * |
Loewe et al, Basic-Substituted 2,6-Bisbenzimidazole Derivatives, a Novel Series of Substances with Chemotherapeutic Activity, J. Arzneim.-Forsch. (Drug Res.), 24:1927-1933 (1974) (with transl.). |
Marcus, Clinical Photodynamic Therapy: The Continuing Evolution, pp. 219 268. * |
Marcus, Clinical Photodynamic Therapy: The Continuing Evolution, pp. 219-268. |
Martin et al, Comparative Studies of UV induced DNA Cleavage by Structural Isomers of an Iodinated DNA Ligand, Int. J. Radiat. Oncol. Biol. Phys. (in press) (1993). * |
Martin et al, Comparative Studies of UV-induced DNA Cleavage by Structural Isomers of an Iodinated DNA Ligand, Int. J. Radiat. Oncol. Biol. Phys. (in press) (1993). |
Martin et al, Cytotoxicity of an 125 I labelled DNA binding Compound that Induces Double Stranded DNA Breaks, Cancer Res ., 39:3244 3247 (1979). * |
Martin et al, Cytotoxicity of an 125 I-labelled DNA-binding Compound that Induces Double-Stranded DNA Breaks, Cancer Res., 39:3244-3247 (1979). |
Martin et al, DNA Damage by Auger Emitters, Taylor & Francis, pp. 55 68 (1988). * |
Martin et al, DNA Damage by Auger Emitters, Taylor & Francis, pp. 55-68 (1988). |
Martin et al, DNA: A Molecular Framework for Studying Reactive Species, Recueil des Travaux Chimiques des Pays Bas , 106:178 (1987). * |
Martin et al, DNA: A Molecular Framework for Studying Reactive Species, Recueil des Travaux Chimiques des Pays-Bas, 106:178 (1987). |
Martin et al, Preparation of Carrier Free 125 I IodoHoechst 33258, Int. J. Appl. Radiat. Isot ., 36(9):745 747 (1985). * |
Martin et al, Preparation of Carrier Free[125 I]IodoHoechst 33258, Int. J. Appl. Radiat. Isot., 36(9):745-747 (1985). |
Martin et al, Rapid Communication, Radiation Sensitization by an Iodine labelled DNA Ligand, Int. J. Radiat. Biol ., 57(5):939 946 (1990). * |
Martin et al, Rapid Communication, Radiation Sensitization by an Iodine-labelled DNA Ligand, Int. J. Radiat. Biol., 57(5):939-946 (1990). |
Martin et al, Synthesis and Characterization of 2 Iodo 4 5 (4 methylpiperazin 1 yl) 2 ,5 bi 1H benzimidazol 2 yl phenol (iodoHoechst 33258) and 2,5 Disubstituted Benzimidazole Model Compounds, Aust. J. Chem ., 39:373 381 (1986). * |
Martin et al, Synthesis and Characterization of 2-Iodo-4-[5"-(4'"-methylpiperazin-1'"-yl)-2",5'-bi-1H-benzimidazol-2'-yl]phenol (iodoHoechst 33258) and 2,5-Disubstituted Benzimidazole Model Compounds, Aust. J. Chem., 39:373-381 (1986). |
Martin et al, Synthesis and N.M.R. Spectra of Substituted Aminoiodoacridines, Aust. J. Chem ., 32:2637 2646 (1979). * |
Martin et al, Synthesis and N.M.R. Spectra of Substituted Aminoiodoacridines, Aust. J. Chem., 32:2637-2646 (1979). |
Martin et al, Use of an 125 I labelled DNA Ligand to Probe DNA Structure, Nature , 302(5907):452 454 (1983). * |
Martin et al, Use of an 125 I-labelled DNA Ligand to Probe DNA Structure, Nature, 302(5907):452-454 (1983). |
Martin et al. Chem. Abstr. No. 106:32923b, p. 539, 1987; Aus. J. Chem. 39(2):373 381, 1986. * |
Martin et al. Chem. Abstr. No. 106:32923b, p. 539, 1987; Aus. J. Chem. 39(2):373-381, 1986. |
Martin et al. Chemical Abstracts 93:46379d, 1980, Aust. J. Chem. 32(12):2637 2646, 1979. * |
Martin et al. Chemical Abstracts 93:46379d, 1980, Aust. J. Chem. 32(12):2637-2646, 1979. |
Martin, Induction of Double Stranded Breaks in DNA by Binding with an 125 I labelled Acridine, Int. J. Radiat. Biol ., 32(5):491 497 (1977). * |
Martin, Induction of Double-Stranded Breaks in DNA by Binding with an 125 I-labelled Acridine, Int. J. Radiat. Biol., 32(5):491-497 (1977). |
Murray et al, Sequence Specificity of 125 I labelled Hoechst 33258 Damage in Six Closely Related DNA Sequences, J. Mol. Biol ., 203:63 73 (1988). * |
Murray et al, Sequence Specificity of 125 I labelled Hoechst 33258 in Intact Human Cells, J. Mol. Biol ., 201:437 442 (1988). * |
Murray et al, Sequence Specificity of 125 I-labelled Hoechst 33258 Damage in Six Closely Related DNA Sequences, J. Mol. Biol., 203:63-73 (1988). |
Murray et al, Sequence Specificity of 125 I-labelled Hoechst 33258 in Intact Human Cells, J. Mol. Biol., 201:437-442 (1988). |
Murray et al, The Degree of Ultraviolet Light Damage to DNA Containing Iododeoxyuridine or Bromodeoxyuridine is Dependent on the DNA Sequence, Nucleic Acids Res ., 17(7):2675 2691 (1989). * |
Murray et al, The Degree of Ultraviolet Light Damage to DNA Containing Iododeoxyuridine or Bromodeoxyuridine is Dependent on the DNA Sequence, Nucleic Acids Res., 17(7):2675-2691 (1989). |
Murray et al. J. Mol. Biol. 201:437 442, 1988. * |
Murray et al. J. Mol. Biol. 201:437-442, 1988. |
Ridley et al, A New Synthesis of Benzimidazoles and Aza analogs, J. Het. Chem ., 2:453 456 (1965). * |
Ridley et al, A New Synthesis of Benzimidazoles and Aza-analogs, J. Het. Chem., 2:453-456 (1965). |
Rodriguez et al, Continuous Infusion of Halogenated Pyrimidines, I. J. Radiation Oncology, Biology, Phsics , 20(6):1380 1381 (1991). * |
Rodriguez et al, Continuous Infusion of Halogenated Pyrimidines, I. J. Radiation Oncology, Biology, Phsics, 20(6):1380-1381 (1991). |
Russell et al, In Vitro and in Vivo Radiation Sensitization by the Halogenated Pyrimidine 5 Chloro 2 deoxycytidine, Cancer Res ., 46:2883 2887 (1986). * |
Russell et al, In Vitro and in Vivo Radiation Sensitization by the Halogenated Pyrimidine 5-Chloro-2'-deoxycytidine, Cancer Res., 46:2883-2887 (1986). |
Sano et al. Chem. Abstr. No. 70:6805, p. 672, 1969; No to Shinkei, 19:339 344, 1967. * |
Sano et al. Chem. Abstr. No. 70:6805, p. 672, 1969; No to Shinkei, 19:339-344, 1967. |
Smith et al. Chem. Abstr. 102:92205w, p. 269, 1985; Int. J. Radiation Biol. Relat. Stud. Phys. Chem. Med. 46(4): 331 334, 1984. * |
Smith et al. Chem. Abstr. 102:92205w, p. 269, 1985; Int. J. Radiation Biol. Relat. Stud. Phys. Chem. Med. 46(4): 331-334, 1984. |
Teng et al, The Molecular Structure of the Complex of Hoechst 33258 and the DNA Dodecamer d(CGCGAATTCGCG), Nucleic Acids Res ., 16(6):2671 2690 (1988). * |
Teng et al, The Molecular Structure of the Complex of Hoechst 33258 and the DNA Dodecamer d(CGCGAATTCGCG), Nucleic Acids Res., 16(6):2671-2690 (1988). |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6194414B1 (en) * | 1995-07-28 | 2001-02-27 | The Inner And Eastern Health Care Network | Radioprotectors |
US6548505B1 (en) * | 1995-07-28 | 2003-04-15 | Peter Maccallum Cancer Institute | Radioprotectors |
US8974363B2 (en) | 1997-12-11 | 2015-03-10 | Provectus Pharmatech, Inc. | Topical medicaments and methods for photodynamic treatment of disease |
US20080118578A1 (en) * | 1997-12-11 | 2008-05-22 | Dees H Craig | Topical Medicaments and Methods for Photodynamic Treatment of Disease |
US20080118567A1 (en) * | 1998-08-06 | 2008-05-22 | Provectus Pharmatech. Inc, | Medicaments for Chemotherapeutic Treatment of Disease |
US20090117199A1 (en) * | 1998-08-06 | 2009-05-07 | Scott Timothy C | Method of treatment of cancer |
US8557298B2 (en) | 1998-08-06 | 2013-10-15 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
US20040047804A1 (en) * | 1998-10-29 | 2004-03-11 | The General Hospital Corporation, A Massachusetts Corporation | Enhanced radiation therapy |
US8470296B2 (en) | 1998-12-21 | 2013-06-25 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US20020001567A1 (en) * | 1998-12-21 | 2002-01-03 | Photogen, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US7384623B1 (en) | 1998-12-21 | 2008-06-10 | Provectus Pharmatech, Inc. | High energy phototherapeutic agents |
US20070078076A1 (en) * | 1998-12-21 | 2007-04-05 | Xantech Pharmaceuticals, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US20070208076A1 (en) * | 1998-12-21 | 2007-09-06 | Dees H C | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US6331286B1 (en) | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
US6547812B1 (en) * | 2000-12-29 | 2003-04-15 | Advanced Cardiovascular Systems, Inc. | Radiation therapy using a radioactive implantable device and a radiosensitizer agent |
WO2003011219A3 (en) * | 2001-07-27 | 2004-09-23 | Curis Inc | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US20050085519A1 (en) * | 2001-07-27 | 2005-04-21 | Rubin Lee L. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
AU2002327390B2 (en) * | 2001-07-27 | 2008-06-26 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
JP4658473B2 (en) * | 2001-07-27 | 2011-03-23 | キュリス,インコーポレイテッド | Hedgehog signaling pathway mediators, related compositions and uses |
US8354397B2 (en) | 2001-07-27 | 2013-01-15 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
JP2005507860A (en) * | 2001-07-27 | 2005-03-24 | キュリス インコーポレイテッド | Hedgehog signaling pathway mediators, related compositions and uses |
US8772275B2 (en) | 2001-07-27 | 2014-07-08 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2003011219A2 (en) * | 2001-07-27 | 2003-02-13 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US20050080019A1 (en) * | 2002-09-05 | 2005-04-14 | Nanodynamics Inc. | Radiotherapy method using x-rays |
US7981928B2 (en) | 2002-09-05 | 2011-07-19 | Nanodynamics, Inc. | Chemotherapy method using x-rays |
US8278315B2 (en) | 2002-09-05 | 2012-10-02 | Chia-Gee Wang | Radiotherapy method using x-rays |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US20040191843A1 (en) * | 2003-02-03 | 2004-09-30 | Palo Alto Institute Of Molecular Medicine | Cell-killing molecules and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5641764A (en) | Halogenated DNA ligand radiosensitizers for cancer therapy | |
Dedon et al. | Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin | |
Hartley et al. | DNA alkylation and interstrand cross-linking by treosulfan | |
Christner et al. | Unmasking the chemistry of DNA cleavage by the esperamicins: modulation of 4'-hydrogen abstraction and bistranded damage by the fucose-anthranilate moiety | |
JP4222628B2 (en) | Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purification of leukemia | |
Sage et al. | Sequence context effects on 8-methoxypsoralen photobinding to defined DNA fragments | |
Payet et al. | Instability of the monofunctional adducts in cis-[Pt (NH 3) 2 (N7-N-methyl-2-diazapyrenium) CI] 2+;-modified DNA: rates of cross-linking reactions in cis-platinummodified DNA | |
BRPI0411582A (en) | hydrolytically resistant boron-containing therapeutic substances and method of use | |
Brent et al. | Formation of covalent complexes between human O 6 alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides | |
Robson et al. | A novel human stress response-related gene with a potential role in induced radioresistance | |
Gasparro et al. | Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation | |
US5256648A (en) | Selective inhibition of gene expression by photoactivatable oligonucleotides | |
Moysan et al. | Formation of cyclobutane thymine dimers photosensitized by pyridopsoralens: quantitative and qualitative distribution within DNA | |
ATE404226T1 (en) | COMPOSITION CONTAINING RADIOISOTOPES IMMOBILIZED ON SOLID PARTICLES AND THEIR USE IN BRACHYTHERAPY | |
WO1990012321A1 (en) | Halogenated dna ligand radiosensitisers for cancer therapy | |
Kim et al. | Enhancement of the radiation response of cultured tumor cells by chloroquine | |
AU639920B2 (en) | Halogenated dna ligand radiosensitisers for cancer therapy | |
Wright et al. | A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts | |
Shim et al. | Photocycloaddition of 5, 7‐dimethoxycoumarin to thymine | |
JP3007412B2 (en) | Halogenated DNA ligand radiosensitizers for cancer treatment | |
WO1989006702A1 (en) | Selective inhibition of gene expression by photoactivatable oligonucleotides | |
Hardwick et al. | Ethidium binding sites on plasmid DNA determined by photoaffinity labeling. | |
Laverick et al. | Potentiation of the radiation response of hypoxic mammalian cells by cis-dichlorobis (isopropylamine) trans-dihydroxy platinum IV (CHIP) | |
Hartley et al. | Novel cytotoxic DNA sequence and minor groove targeted photosensitizers: Conjugates of pyrene and netropsin analogues | |
GEP19991535B (en) | Process for the Preparation of 7-Hydroxy Taxanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ANTI-CANCER COUNCIL OF VICTORIA, AUSTRALIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST AND THIRD ASSIGNEES NAME ON AN INSTRUMENT PREVIOUSLY RECORDED AT REEL 6790, FRAME 0822;ASSIGNORS:MARTIN, ROGER F.;KELLY, DAVID P.;REEL/FRAME:008023/0877 Effective date: 19931119 Owner name: PETER MACCALLUM INSTITUTE, AUSTRALIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST AND THIRD ASSIGNEES NAME ON AN INSTRUMENT PREVIOUSLY RECORDED AT REEL 6790, FRAME 0822;ASSIGNORS:MARTIN, ROGER F.;KELLY, DAVID P.;REEL/FRAME:008023/0877 Effective date: 19931119 Owner name: UNIVERSITY OF MELBOURNE, AUSTRALIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST AND THIRD ASSIGNEES NAME ON AN INSTRUMENT PREVIOUSLY RECORDED AT REEL 6790, FRAME 0822;ASSIGNORS:MARTIN, ROGER F.;KELLY, DAVID P.;REEL/FRAME:008023/0877 Effective date: 19931119 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: PETER MACCALLUM CANCER INSTITUTE, AUSTRALIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE, FILED ON 08/07/96 RECORDED ON REEL 8023 FRAME 0877;ASSIGNORS:MARTIN, ROGER F.;KELLY, DAVID P.;REEL/FRAME:009845/0001 Effective date: 19931119 Owner name: UNIVERSITY OF MELBOURNE, AUSTRALIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE, FILED ON 08/07/96 RECORDED ON REEL 8023 FRAME 0877;ASSIGNORS:MARTIN, ROGER F.;KELLY, DAVID P.;REEL/FRAME:009845/0001 Effective date: 19931119 Owner name: ANTI-CANCER COUNCIL OF VICTORIA, AUSTRALIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE, FILED ON 08/07/96 RECORDED ON REEL 8023 FRAME 0877;ASSIGNORS:MARTIN, ROGER F.;KELLY, DAVID P.;REEL/FRAME:009845/0001 Effective date: 19931119 |
|
AS | Assignment |
Owner name: ANTI-CANCER COUNCIL OF VICTORIA, AUSTRALIA Free format text: CHANGE OF NAME;ASSIGNOR:PETER MACCALLUM CANCER INSTITUTE;REEL/FRAME:010061/0683 Effective date: 19960701 Owner name: INNER AND EASTERN HEALTH CARE NETWORK, AUSTRALIA Free format text: CHANGE OF NAME;ASSIGNOR:PETER MACCALLUM CANCER INSTITUTE;REEL/FRAME:010061/0683 Effective date: 19960701 Owner name: MELBOURNE, UNIVERSITY OF, AUSTRALIA Free format text: CHANGE OF NAME;ASSIGNOR:PETER MACCALLUM CANCER INSTITUTE;REEL/FRAME:010061/0683 Effective date: 19960701 |
|
AS | Assignment |
Owner name: INNER AND EASTERN HEALTH CARE NETWORK, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MELBOURNE, UNIVERSITY OF;ANTI-CANCER COUNCIL OF VICTORIA;REEL/FRAME:010263/0005 Effective date: 19980625 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: PETER MACCALLUM CANCER INSTITUTE, AUSTRALIA Free format text: ALLOCATION OF PROPERTY, RIGHTS AND LIABILITES;ASSIGNOR:INNER AND EASTERN HEALTH CARE NETWORK;REEL/FRAME:013392/0624 Effective date: 20000701 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |